NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures

Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue guidance of $2.06 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.74 per share was 24.5% below analysts’ consensus estimates.

Is now the time to buy NTRA? Find out in our full research report (it’s free).

StockStory’s Take

Natera’s second quarter showed significant momentum, with management attributing strong revenue growth to broad-based gains in oncology, particularly from its Signatera minimal residual disease (MRD) test. CEO Steven Chapman highlighted a record number of new patient starts, driven by positive clinical trial results and greater physician adoption across tumor types. The company also saw continued progress in women’s health and organ health, underscored by new product launches and expanded clinical evidence. Gross margin expansion was supported by improved average selling prices and operational efficiencies, though increased costs tied to higher test volumes and investments in innovation weighed on operating margins.

Looking ahead, Natera’s updated guidance reflects management’s confidence in continued revenue growth, supported by expanded Medicare coverage opportunities and a robust clinical trial pipeline in oncology. Chapman emphasized the anticipated impact of new product launches and ongoing investments in artificial intelligence (AI) to drive efficiencies and future diagnostic capabilities. Management expects recent salesforce expansions to contribute meaningfully in late 2025 and beyond as new hires ramp up productivity. CFO Michael Brophy noted, “Our forecast assumes further improvement in gross margins as ASPs rise and cost initiatives take hold, but also recognizes ongoing investment in R&D and commercialization to sustain long-term growth.”

Key Insights from Management’s Remarks

Management attributed second quarter outperformance to strong demand for Signatera, new clinical evidence supporting reimbursement, and momentum in product launches across oncology, women’s health, and organ health.

• Oncology adoption surge: Signatera saw robust growth, with a record-setting increase in new patient starts. Management credited recent clinical trial results, such as those presented at major oncology conferences, for spurring greater physician adoption across a broader range of tumor types beyond colorectal and breast cancer.

• Women’s health product launch: The introduction of Fetal Focus, a non-invasive prenatal test (NIPT) for inherited conditions, was highlighted as a key development. Backed by early data from the EXPAND validation study, this product aims to fill a gap in risk assessment when paternal testing is unavailable, leveraging Natera’s proprietary SNP-based technology.

• Organ health momentum: Prospera, Natera’s organ transplant rejection test, benefited from new data published in a top medical journal, demonstrating its utility in monitoring kidney transplant recipients. Management noted increased adoption among major transplant centers and positive reimbursement trends as drivers.

• Margin improvement levers: The company outlined four main strategies for future margin expansion: (1) continued optimization of revenue cycle operations, (2) expanded payer coverage for products, (3) cost reductions through R&D, and (4) operational efficiencies enabled by AI. Early results from investments in revenue cycle management and automation have already reduced days sales outstanding (DSO) and improved cash conversion.

• AI and product pipeline advances: Natera is deploying AI across its operations, including user experience tools, diagnostic algorithm development, and support for clinical trial matching. Management believes these initiatives can unlock substantial cost savings and open new revenue streams, particularly through partnerships with pharmaceutical companies.

Drivers of Future Performance

Natera’s outlook for the rest of 2025 is defined by continued oncology adoption, revenue cycle optimization, and investments in AI, balanced against persistent R&D and commercialization expenses.

• Expanded coverage opportunities: Management is focused on securing additional Medicare reimbursement for Signatera across more cancer types. If achieved, this could add $250–$300 million in annual revenue, with several submissions expected within the next 12–18 months. However, timelines depend on generating robust clinical data and navigating payer requirements.

• Salesforce productivity ramp: The company recently increased its oncology salesforce, expecting a lag before these new hires deliver measurable revenue contributions. Management described a "slingshot effect," where expenses precede revenue impact, with meaningful productivity gains anticipated in late 2025 and into 2026.

• AI-driven operational leverage: Natera’s ongoing AI investments are expected to deliver cost efficiencies in both laboratory operations and administrative functions. Management projects up to $200 million in long-term savings, as well as the potential to commercialize AI-powered tools through pharma partnerships and next-generation diagnostics.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be monitoring (1) clinical trial readouts, particularly for the PROCEED and IMvigor011 studies, as key indicators of Signatera’s future adoption and reimbursement prospects; (2) evidence of expanded Medicare and commercial payer coverage for additional cancer types and organ health products; and (3) tangible operating leverage from recent AI investments and salesforce expansion. Progress toward commercializing AI-powered diagnostics and securing new pharma partnerships will also be important markers.

Natera currently trades at $158.44, up from $141.45 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.